dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Montalban Gairín, Xavier |
dc.contributor.author | Hu, Xixi |
dc.contributor.author | Kropshofer, Harald |
dc.contributor.author | Kukkaro, Petra |
dc.contributor.author | Coello, Neva |
dc.contributor.author | Bar-Or, Amit |
dc.date.accessioned | 2023-02-17T13:35:33Z |
dc.date.available | 2023-02-17T13:35:33Z |
dc.date.issued | 2023-02 |
dc.identifier.citation | Bar-Or A, Montalban X, Hu X, Kropshofer H, Kukkaro P, Coello N, et al. Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial. Neurol Ther. 2023 Feb;12:303-17. |
dc.identifier.issn | 2193-6536 |
dc.identifier.uri | https://hdl.handle.net/11351/9003 |
dc.description | Biomarcador; Ofatumumab; Esclerosi múltiple recurrent |
dc.description.sponsorship | The study was funded by Novartis Pharma AG. The study sponsor participated in the design and conduct of the study, data collection, data management, data analysis and interpretation, and preparation, review, and approval of the manuscript. The Novartis Pharma AG also sponsored the publication of this manuscript along with its associated rapid service fee. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Neurology and Therapy;12 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Marcadors bioquímics |
dc.subject | Esclerosi múltiple |
dc.subject | Filaments citoplasmàtics |
dc.subject.mesh | Multiple Sclerosis |
dc.subject.mesh | Neurofilament Proteins |
dc.subject.mesh | Biomarkers |
dc.title | Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s40120-022-00427-8 |
dc.subject.decs | esclerosis múltiple |
dc.subject.decs | proteínas de neurofilamentos |
dc.subject.decs | biomarcadores |
dc.relation.publishversion | https://doi.org/10.1007/s40120-022-00427-8 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Bar-Or A] Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. [Montalban X] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Hu X] Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. [Kropshofer H, Kukkaro P, Coello N] Novartis Pharma AG, Basel, Switzerland |
dc.identifier.pmid | 36534274 |
dc.identifier.wos | 000900781700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |